Detection of amiodarone pulmonary toxicity: To screen or not to screen, that is the question!  by Horowitz, Leonard N.
Editorial Comment 
Pulmonary Toxicity: To Screen 
or Not to Screen, T 
Question!* 
wcrc uwfd an ioofirmipg the diagnosis of pulmonary LOX/I:- 
ity. ihey Gould not predict the development of pulmonary 
torlLlt) in n\ymptomatic patte”t5. 
Rote uf preexisting pulmon~~ disease. The advlwbdity of 
inmaung amodarone therapy m pnttents wth presistcnt 
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did no! find a” increared iocadence of pulmonary toxicity in 
wtienl$ with “reeurting lune disease or bavline abnormrd- 
itm m cheu radzographs or diffusing capaciiy and lhcrciore 
ilalcd that there is “no rearon that am~odarone cannot be 
gave” ufclv 10 most patients regardless of preaiwing pul- 
11 is now undisputed that amiodarone. a potcnr and eRccirve monaty ctatn,.” Others ;4.7,81. however. havz found an 
antiarrhythmic agent. can produce a variety of tone pulmo- Incrcawd mudence of @“on;rry toxicity I” pat,enrs wth 
nary syndromes. Debate conlinues. however. ahout the lung dnea~ and have recommended Ihat such patients be 
incidence of this toxicity and the appropriate measures that convdered for altcrnattve therapy. This variability in the 
should be take” to detect and treat it. The incidence of incidescc of pulmonary toxicny in patien!s with precxtsting 
amiodaro”e pulmonary toxicny has been esumated to be as pulmonilry direace may he due to a !xk of undormny in 
lowas <I% and as highas >2O%a”d the monalny rate fror. triteno wed for defining holh 1be presence of preexisting 
this complication of amiadarone therapy has ranged as htgh pulmonsry dwace and the presence of ammdarone polrw 
as IO to 20% (1-61. Whereas there is no co”se”sus on its nary toxicity. This disagreement IF not of monumental 
incidence. there appears to be general agreement that this consequence. I cannot. h wever. agree wth the generaliza- 
type of toxicity is serious. Moreover, there is a perceptm” lion of Magro et al. that thetc :\ no reason to avoid 
that if the syndrome could be detected in a prcclinical or ami.ldarons I” patents with preexisting pulmonary dtscasc. 
asymptomatic phase, its management would be Easter and Eve” If such pathems are not at increased ripk of developing 
the morbidity and we” mortalby from it could be reducer’. pulmonary Loricity. they cenarniy woold tolerate it le\> wcII. 
Thus we hear the age old quesrion that applies 10 cardiology Pulmonary toxicity is not an uncommon went. occurring in 
as it does to all other medical specialties-to screc” or not to “early 20% ofpatients reported on by Magro et 81. (I b. and in 
screen? patient wtth oreexisting ~ulmonarv disease. oarticularlv if it 
In the ctwent issue of the Journal. Magro et al. c I) report 
the results of a prospective evaluation of serial vulmonary 
funClio” testing in patients treated with amiodarone. The; 
made several interesting and clinically important observa- 
dons. The presence of significant pulmonary disease. defined 
as an abnormal baseline diffusing capacity with or without a” 
abnormal chest radiograph, before the initiation of amioda- 
rone therapy was not a risk factor for the development of 
pulmonary toxicity. Several variables measured during pul- 
/s severe. the sttpe&p&ition oi amiodar&e pul&“ary 
toxicity -wght present a severe and eve” fatal complication. 
Whether or not there is a” mcreased incidence of omioda- 
rone pulmooarj toxicity in paaiiemr wish preexistmg long 
direae. nltcrnative therapy should he sought in such pa- 
lientr and amiodarone rzrerved for only the most resistant 
CBBOE. 
Role of pulmonary fwtion testing. Magro et al. l/l 
showed that careful serial meawrement of oulmunarv func- 
monary function testing changed sigeificatly in patient, 
with amndarone pulmonary taxicily. but the most rignifi- 
lion studies can detect coos~swm changes in severei varia- 
blcr. particularly the diffusing capacity for carbon dioxide. 
cant change was noted in the diffusing capacity for carbon 
monoxide. A 1.5% decrease in this variable gave optimal 
when amiodaronc-induced pulmonary toxicity develops. 
They found that a ~15% decrease ia the difiusing capacity 
sensitivity and specificity fo! lhe di:lpnosis of pulmonary identified the presence of pulmonary toxicity with a sensi- 
tivitv of loO% and a scecificitv of 89%. This is a” imuortant 
wllonah Q”blkhd 1” hrrm”, “, ,,w ,4r,wKa,E CdPp q, C”rdd,,~~ 
ob&tio”. During’ amiod&one therapy, patie& fre- 
re”Ca Ihe view* ar the avlhorr und ‘Jo no, ,w.cn;n,y ICPRIen, ihe we_ “f 
qurntly prebennt with “ew or worsening respiratory symp 
JACC or rile &ndcan coucge of Cardxolo~y tome and pulmonary findings and the diffusing capacity is a 
FKlrn dlc Phlladelphll Hea” l”ILil,,,.. Pic\byle”u”.“s”cr,,ly ur Penn 
lylvania Medal center. Philadalph,a. Pe”“\yIYa”la. 
readily avadable variable that may help to distinguish pul- 
v: Leonard N Ha,ow,tr, MD. wallrlphlp. Hl”” 
monary txicity from other common problems. Their results 
,mdtutr. Pmrbyterian-U”i”erriry of Pen”5yl”anla f&d,ca, Ccn,w. 19,h and are not startling in that several other groups (3-5) have 
Mar!w stteotr. Pb,ladelph,a. P.nniylra”ia. suggested that changes in pulmonary function tests might 
distmgursh patient\ with from those without pulmonary 
toxicity. It nou nppf.srs that if a patient who is receiving 
amiodarone therapy develops respiratory symptomr or ab- 
nnnnabtiec on physial examination or chest radiograph. the 
diffusing capacity may be a useful discriminator of amioda- 
ronc pulmonary toxicity I Xore pallium scanning. or bmpsy. 
Before widespread accepiance of this suggcsfion, however, 
confirmation by another prospective study would be desir- 
able. If correct. a baseline pulmonary function test not only 
would be advisable bu: should be mandatory. 
Is routine screening by serial pulmonary function testing 
advisable? Now that it appears that the diffusing capacity 
MF be useful in discriminaring amiodarone-induced pulmo- 
nary toxicity from other pulmonary syndromes that com- 
monly nccur in palients receiving amiodarnne, it is reason- 
able to ask whether routine serial screening is advisable. 
Magm er al. I It found that decreases in ditTusing capacity are 
not useful in prospective identification of patients who are 
likely to develop pulmonary toxicity or are in an arympto- 
matic preclinical phase of that complication. Many patients 
developed a 15% decrease in diffusing capacity, which 
subsequently nornmlired. and other patients maintained the 
decrearcd dilfusing rapacity without developing clinical ev- 
idence of toxicity. Other investigators (4.5) also have oh- 
served conaiderablc variation in pulmonary function tests in 
patients receiving amiodarnne therapy. Because oi this 
variability. neitheralteration in dosing nor discontinuation of 
amiodarnne nor more aggressive evaluations (e.g.. gallium 
scanning or biopsy) can be recommended when a change in 
the ditTusing capacity is observed in the absence of symp- 
toms. 
In the studies that have reported serial pulmonary func- 
tion testmg in patients receiving amiodarune, cost and lack 
of patient acceptance of Ihip diagnostic tezt are rarely 
menrioned. Pulmonary function testing can be uncomfurt- 
able. particularly when arterial blood gas measurement is 
included. The cat of pulmonary function testing is not 
inconsiderable (ranging from S400 tn $fKM in the United 
Slatc9. In fact. the cost of screening pulmonary function 
studies may equal or exceed the cost of the amiodarnne 
itself. nor an inexpensive antiarrhythmic agent 61.309lyear 
in the average maintenance dose). 
Amiodarone pulmonary toxicity is not an uncnrnmcm 
complication and may have devastating consequences. It 
would be desirable tn delcct this syndrome before it devel- 
ops or in an early phase to minimize its impact. Thus, it is 
reasonable to ask whether WC can fight amiodarone pulmo- 
nary toxicity with a “check-up and a check (for the pulmo- 
nary function studies).” With present techniques of pulmo- 
nary function testir.;, the answer appears tn be no. Thus WP 
cn,, conclnde: 
